XBiotech (XBIT) Osake Kurssi
XBiotech Kurssi
XBiotechn liikevaihto on supistunut 60,8 % vuodessa viimeisten 4 vuoden aikana 300 000,00 USD:een. XBiotechn nettomarginaali −8 185,7 % on laskenut verrattuna 5 272,7 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 1,14 %.
XBiotech osakekurssi
XBiotech liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset XBiotech -osakkeesta
The business model of XBiotech Inc is focused on developing antibody therapies to treat various diseases. XBiotech utilizes its True HumanTM antibody technology to discover and develop antibodies that target specific diseases and conditions. The company's approach involves isolating and characterizing natural antibodies produced by the human immune system in response to certain diseases. These antibodies are then utilized as potential therapeutic candidates. XBiotech's business model involves conducting preclinical and clinical studies to evaluate the safety and efficacy of their antibody therapies, seeking regulatory approvals, and potentially partnering with pharmaceutical companies for commercialization. The company aims to improve patient outcomes and bring innovative antibody therapies to market.
XBiotech Inc is primarily active in the biotechnology industry.
The main competitors of XBiotech Inc in the market include pharmaceutical companies such as Amgen Inc., Johnson & Johnson, and Eli Lilly and Company.
XBiotech Inc, a biopharmaceutical company, was founded in 2005 and is headquartered in Austin, Texas. With a focus on discovering and developing True Human™ monoclonal antibodies, the company aims to revolutionize the treatment of various diseases, including cancer and inflammatory disorders. XBiotech Inc is known for its unique approach, harvesting antibodies from natural human immune responses instead of artificial means. This innovative technique allows the company to produce exceptionally pure therapeutic antibodies, offering potential benefits to patients. XBiotech Inc's commitment to advancing medical solutions underscores their dedication to improving global healthcare outcomes.
XBiotech Inc has achieved significant milestones since its inception. The company successfully developed and gained FDA approval for its monoclonal antibody therapy, Xilonix, which targets inflammatory conditions. Additionally, XBiotech Inc performed a successful Phase III clinical trial for Xilonix in advanced colorectal cancer patients. Moreover, the company has expanded its pipeline by initiating clinical trials for other conditions such as Hidradenitis Suppurativa. XBiotech Inc has also established important collaborations with leading pharmaceutical companies, enhancing its research capabilities and market presence. These achievements highlight XBiotech Inc's commitment to innovation, clinical excellence, and dedication to improving the lives of patients.
XBiotech Inc is primarily present in the United States, focusing on the development and commercialization of innovative therapies for various diseases.
XBiotech Inc represents values of innovation, patient-centeredness, and scientific rigor. The company's corporate philosophy revolves around developing groundbreaking therapies to improve patient outcomes. XBiotech Inc aims to advance the understanding and treatment of diseases by utilizing cutting-edge research and technology. With a focus on delivering customized treatments, the company prioritizes patient needs and strives to make a positive impact on individuals' lives. XBiotech Inc is dedicated to fostering a culture of collaboration, integrity, and ethical practices within the organization. Through its commitment to excellence, XBiotech Inc continues to make significant contributions to the healthcare industry.
7 analyytikkoa arvioi tällä hetkellä XBiotech-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla XBiotech-osake noteerataan hintaan 1,96 EUR (2,19 USD).
XBiotech-osake (XBIT) on listattuna 5 pörssissä, muun muassa: NASDAQ (XBIT), SIX (Zürich) (4XB.SW), Frankfurt (4XB.F), München (4XB.MU), Düsseldorf (4XB.DU).
XBiotech Inc is a biopharmaceutical company focused on the discovery and development of therapeutics for serious diseases. The company was founded in 2005 and is headquartered in Austin, Texas. The business model of XBiotech is based on the clinical development and commercialization of monoclonal antibodies for the treatment of cancer and chronic inflammatory diseases. The company produces antibodies against cytokines responsible for inflammatory reactions in the human body. XBiotech has developed a comprehensive approach to antibody discovery based on the identification of natural antibodies from the blood of healthy individuals. These antibodies have already shown the ability to target a variety of diseases and therefore have high potential for the development of new therapeutics. The flagship product of XBiotech is the antibody Xilonix. It has been developed for the treatment of metastatic colorectal cancer and has shown in clinical studies the ability to reduce symptoms and improve quality of life for cancer patients. XBiotech recently completed a Phase III study and plans to submit the antibody for regulatory approval soon. In addition, XBiotech is working on the development of antibodies against other diseases such as Alzheimer's, melanoma, and rheumatoid arthritis. The company has made promising progress in these areas as well. Another important aspect of XBiotech's business model is partnerships with other companies. The company aims to establish strong partnerships with pharmaceutical companies to bring new products to the market together. This allows XBiotech to fully leverage the potential of its technology and provide better treatment for patients worldwide. An example of this is the partnership with Janssen Biotech, a subsidiary of Johnson & Johnson. The two companies are working together on the development of antibodies against the cytokine Interleukin-1a (IL-1a), which is involved in the development of various chronic inflammatory diseases. Furthermore, the production of the antibody is significantly more cost-effective and faster through XBiotech's proprietary technology compared to conventional manufacturing methods. Overall, XBiotech has developed a promising business model based on innovative technology and dedicated research and development. The company has already made significant progress and will continue to make important contributions to the development of new therapies for patients with serious diseases. The answer is: XBiotech Inc is a biopharmaceutical company focused on the discovery and development of therapeutics for serious diseases.
Liikevaihtoa ei voida laskea XBiotech:lle tällä hetkellä.
Voittoa ei voida laskea XBiotech:lle tällä hetkellä.
P/E-suhdetta ei voida laskea XBiotech:lle tällä hetkellä.
P/S-suhdetta ei voida laskea XBiotech:lle tällä hetkellä.
XBiotech:n Eulpool-laatuscore on 2/10.
XBiotech:n ISIN on CA98400H1029. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
XBiotech:n WKN on A14QF1. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
XBiotech:n ticker on XBIT. Tämä pörssinoteeraus käytetään XBiotech-osakkeiden kauppaan pörssissä.
XBiotech osake
XBiotech vertaisryhmä
XBiotech Ticker
XBiotech FIGI
Kaikki tunnusluvut ja syvällinen analyysi XBiotech:sta
Meidän osakeanalyysimme XBiotech-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut XBiotech:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: